STOCK TITAN

Ekso Bionics SEC Filings

EKSO NASDAQ

Welcome to our dedicated page for Ekso Bionics SEC filings (Ticker: EKSO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Ekso Bionics Holdings Inc. filings document material-event disclosures, financing arrangements, governance actions, capital-structure changes, and operating results for an exoskeleton technology issuer. The company’s Form 8-K disclosures include financial results, material agreements, shareholder voting matters, and security-structure information tied to preferred stock, warrants, and other corporate actions.

Regulatory filings also cover a private placement of Series B Convertible Preferred Stock and warrants, a secured term loan involving subsidiary Ekso Bionics, Inc. as guarantor, equity awards under the company’s Amended and Restated 2014 Equity Incentive Plan, and governance matters associated with the company’s corporate transition.

Rhea-AI Summary

ChronoScale Corporation, formerly Ekso Bionics Holdings, Inc., is amending previously disclosed phantom performance-based stock unit awards for three senior executives. The awards, granted on November 5, 2025, totaled 185,000 Phantom PSUs for Scott G. Davis, 40,000 for Jerome Wong, and 32,000 for Jason Jones.

The Board determined on May 14, 2026 that the stock price goal was achieved and that the May 5, 2026 closing of a Contribution and Exchange Agreement constituted a Change in Control, satisfying vesting conditions. Settlement has been changed from cash-only to equity and cash.

Mr. Davis’s award will now settle in 109,357 shares of common stock plus a $1,000,000 cash payment, while Mr. Wong and Mr. Jones will receive 40,000 and 32,000 shares of common stock, respectively. Payments and share issuances will occur after the closing and no later than March 15, 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

ChronoScale Corporation, formerly Ekso Bionics Holdings, Inc., is amending previously disclosed phantom performance-based stock unit awards for three senior executives. The awards, granted on November 5, 2025, totaled 185,000 Phantom PSUs for Scott G. Davis, 40,000 for Jerome Wong, and 32,000 for Jason Jones.

The Board determined on May 14, 2026 that the stock price goal was achieved and that the May 5, 2026 closing of a Contribution and Exchange Agreement constituted a Change in Control, satisfying vesting conditions. Settlement has been changed from cash-only to equity and cash.

Mr. Davis’s award will now settle in 109,357 shares of common stock plus a $1,000,000 cash payment, while Mr. Wong and Mr. Jones will receive 40,000 and 32,000 shares of common stock, respectively. Payments and share issuances will occur after the closing and no later than March 15, 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

CLANCY WILLIAM M reported acquisition or exercise transactions in this Form 4 filing.

ChronoScale Corp director William M. Clancy received a grant of 200,000 restricted shares of common stock as equity compensation. The shares were awarded at no cash purchase price and are held directly.

According to the vesting schedule, 100,000 restricted shares will vest on the one-year anniversary of the May 14, 2026 grant date, and another 100,000 will vest on the two-year anniversary. Vesting requires his continuous service with the company through each vesting date, with potential adjustments or accelerated vesting under certain conditions. After this grant, Clancy owns 200,000 shares of ChronoScale common stock directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

CLANCY WILLIAM M reported acquisition or exercise transactions in this Form 4 filing.

ChronoScale Corp director William M. Clancy received a grant of 200,000 restricted shares of common stock as equity compensation. The shares were awarded at no cash purchase price and are held directly.

According to the vesting schedule, 100,000 restricted shares will vest on the one-year anniversary of the May 14, 2026 grant date, and another 100,000 will vest on the two-year anniversary. Vesting requires his continuous service with the company through each vesting date, with potential adjustments or accelerated vesting under certain conditions. After this grant, Clancy owns 200,000 shares of ChronoScale common stock directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cummins Wes reported acquisition or exercise transactions in this Form 4 filing.

ChronoScale Corp director Wes Cummins received a grant of 200,000 restricted shares of common stock as equity compensation. The grant was made on May 14, 2026 and all shares are held directly, bringing his reported direct common stock holdings to 200,000 shares.

According to the vesting schedule, 100,000 restricted shares will vest on the one-year anniversary of the grant date and the remaining 100,000 will vest on the two-year anniversary, conditioned on his continuous service with the company and subject to possible adjustment or accelerated vesting upon certain conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Cummins Wes reported acquisition or exercise transactions in this Form 4 filing.

ChronoScale Corp director Wes Cummins received a grant of 200,000 restricted shares of common stock as equity compensation. The grant was made on May 14, 2026 and all shares are held directly, bringing his reported direct common stock holdings to 200,000 shares.

According to the vesting schedule, 100,000 restricted shares will vest on the one-year anniversary of the grant date and the remaining 100,000 will vest on the two-year anniversary, conditioned on his continuous service with the company and subject to possible adjustment or accelerated vesting upon certain conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Benson Ella G. reported acquisition or exercise transactions in this Form 4 filing.

ChronoScale Corp director Ella G. Benson received a grant of 200,000 shares of restricted common stock as compensation. The award was granted on May 14, 2026 at no cash purchase price and brings her direct holdings to 200,000 shares.

The grant vests in two equal tranches. 100,000 restricted shares vest on the one-year anniversary of the grant date, and the remaining 100,000 vest on the two-year anniversary. Vesting is conditioned on Benson’s continuous service with ChronoScale and may be adjusted or accelerated under certain conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Benson Ella G. reported acquisition or exercise transactions in this Form 4 filing.

ChronoScale Corp director Ella G. Benson received a grant of 200,000 shares of restricted common stock as compensation. The award was granted on May 14, 2026 at no cash purchase price and brings her direct holdings to 200,000 shares.

The grant vests in two equal tranches. 100,000 restricted shares vest on the one-year anniversary of the grant date, and the remaining 100,000 vest on the two-year anniversary. Vesting is conditioned on Benson’s continuous service with ChronoScale and may be adjusted or accelerated under certain conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

ChronoScale Corp Chief Financial Officer Jerome Wong reported new equity compensation and updated holdings. He received 40,000 shares of common stock at a price of $0.00 per share as a grant or award acquisition tied to performance-based restricted stock units under the company’s Amended and Restated 2014 Equity Incentive Plan. Following this award, he directly holds 64,771 shares of common stock and indirectly holds 4,184 shares through a 401(k) account.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

ChronoScale Corp Chief Financial Officer Jerome Wong reported new equity compensation and updated holdings. He received 40,000 shares of common stock at a price of $0.00 per share as a grant or award acquisition tied to performance-based restricted stock units under the company’s Amended and Restated 2014 Equity Incentive Plan. Following this award, he directly holds 64,771 shares of common stock and indirectly holds 4,184 shares through a 401(k) account.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Nottenburg Richard N reported acquisition or exercise transactions in this Form 4 filing.

ChronoScale Corp reported that director Richard N. Nottenburg received a grant of 200,000 shares of restricted common stock on May 14, 2026. These shares were awarded at $0.00 per share as equity compensation, not as an open‑market purchase.

According to the vesting schedule, 100,000 restricted shares will vest on the first anniversary of the grant date and another 100,000 restricted shares will vest on the second anniversary. Vesting is conditioned on his continuous service with ChronoScale and may be adjusted or accelerated under certain conditions. After this grant, he directly holds 200,000 ChronoScale shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Nottenburg Richard N reported acquisition or exercise transactions in this Form 4 filing.

ChronoScale Corp reported that director Richard N. Nottenburg received a grant of 200,000 shares of restricted common stock on May 14, 2026. These shares were awarded at $0.00 per share as equity compensation, not as an open‑market purchase.

According to the vesting schedule, 100,000 restricted shares will vest on the first anniversary of the grant date and another 100,000 restricted shares will vest on the second anniversary. Vesting is conditioned on his continuous service with ChronoScale and may be adjusted or accelerated under certain conditions. After this grant, he directly holds 200,000 ChronoScale shares.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

MILLER DOUGLAS S reported acquisition or exercise transactions in this Form 4 filing.

ChronoScale Corp director Douglas S. Miller received a grant of 200,000 restricted shares of common stock as equity compensation. The award was granted on May 14, 2026 at no purchase price. According to the terms, 100,000 restricted shares vest on the one-year anniversary of the grant date and 100,000 vest on the two-year anniversary.

Each vesting tranche requires Miller to remain in continuous service with ChronoScale through the applicable vesting date, and the award may be adjusted or vest earlier under certain specified conditions. After this grant, Miller holds 200,000 shares directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

MILLER DOUGLAS S reported acquisition or exercise transactions in this Form 4 filing.

ChronoScale Corp director Douglas S. Miller received a grant of 200,000 restricted shares of common stock as equity compensation. The award was granted on May 14, 2026 at no purchase price. According to the terms, 100,000 restricted shares vest on the one-year anniversary of the grant date and 100,000 vest on the two-year anniversary.

Each vesting tranche requires Miller to remain in continuous service with ChronoScale through the applicable vesting date, and the award may be adjusted or vest earlier under certain specified conditions. After this grant, Miller holds 200,000 shares directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

ChronoScale Corp director Davis Scott G. reported a new stock award. He received 109,357 shares of common stock at no cost as a grant or award, increasing his direct holdings to 188,134 shares. The filing also notes 373 shares held indirectly through a 401(k) account.

The shares were acquired upon vesting of performance-based restricted stock units originally granted on November 5, 2025 under ChronoScale’s Amended and Restated 2014 Equity Incentive Plan and amended on May 14, 2026, highlighting that this is a compensation-related equity vesting rather than an open-market purchase or sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

ChronoScale Corp director Davis Scott G. reported a new stock award. He received 109,357 shares of common stock at no cost as a grant or award, increasing his direct holdings to 188,134 shares. The filing also notes 373 shares held indirectly through a 401(k) account.

The shares were acquired upon vesting of performance-based restricted stock units originally granted on November 5, 2025 under ChronoScale’s Amended and Restated 2014 Equity Incentive Plan and amended on May 14, 2026, highlighting that this is a compensation-related equity vesting rather than an open-market purchase or sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

ChronoScale Corp director Cummins Wes filed an initial statement of holdings related to Management Incentive Plan Units (MIP Units) tied to the company’s common stock. The filing shows MIP Units tracking 3,563,878 underlying shares of common stock held on a direct basis.

The MIP Units were fully vested upon grant by APLD ChronoScale Management LLC under its Equity Incentive Plan before ChronoScale’s business combination. They are non-voting interests that track the equity appreciation of ChronoScale and have no expiration date. Any sale of the underlying securities requires discretionary approval by APLD ChronoScale Management LLC, and Cummins does not have a unilateral right to cause a sale within 60 days. He also disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

ChronoScale Corp director Cummins Wes filed an initial statement of holdings related to Management Incentive Plan Units (MIP Units) tied to the company’s common stock. The filing shows MIP Units tracking 3,563,878 underlying shares of common stock held on a direct basis.

The MIP Units were fully vested upon grant by APLD ChronoScale Management LLC under its Equity Incentive Plan before ChronoScale’s business combination. They are non-voting interests that track the equity appreciation of ChronoScale and have no expiration date. Any sale of the underlying securities requires discretionary approval by APLD ChronoScale Management LLC, and Cummins does not have a unilateral right to cause a sale within 60 days. He also disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

ChronoScale Corp director Douglas S. Miller has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. The data provided shows no reported buy, sell, or other share transactions in this filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

ChronoScale Corp director Douglas S. Miller has filed a Form 3, which is an initial statement of beneficial ownership for company insiders. The data provided shows no reported buy, sell, or other share transactions in this filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

How many Ekso Bionics (EKSO) SEC filings are available on StockTitan?

StockTitan tracks 75 SEC filings for Ekso Bionics (EKSO), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for Ekso Bionics (EKSO)?

The most recent SEC filing for Ekso Bionics (EKSO) was filed on May 20, 2026.